David E. I. Pyott - 18 Feb 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Director
Issuer ticker: TARS
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 16:35:48 UTC
Prior SEC filing: 09 Jun 2025
Next SEC filing: 28 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Sieckert, Attorney-in-Fact

Key filing fact

David E. I. Pyott filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 20 Feb 2026.

Key facts

This page summarizes David E. I. Pyott's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Feb 2026, 16:35.

Change

Previous filing in this sequence was filed on 09 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001051578 Primary reporting owner

PYOTT DAVID E I

Relationship: Director
Address: C/O TARSUS PHARMACEUTICALS, 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Signature date: 20 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +5,893
Change %
Price: $0.000000
Shares after: 5,893
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,893
Exercise price: $63.27
Footnotes: F1

TARS transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +3,729
Change %
Price: $0.000000
Shares after: 3,729
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,729
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

Footnote F3

The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.